Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 + Rivoceranib +/- SHR-2554 in Advanced Gastric Cancer
NCT07311408Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zeprumetostat in gastric cancer (GC), gastroesophageal junction adenocarcinoma. Started Jan 2026; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07311408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311408.